A Phase 2/3 interventional study of Riboflavin 0.1% ophthalmic solution and pulsed light and Riboflavin 0.1% ophthalmic solution and non-pulsed light in Keratoconus and Corneal Ectasia, sponsored by Price Vision Group. Recruiting at 1 site in United States. Open to participants aged 10 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Price Vision Group · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing riboflavin in Keratoconus — 5 open to participants now, 8 under way, 7 of them phase 3. Riboflavin · Keratoconus.
Among the 23 studies testing riboflavin in Keratoconus, this one is the 5th largest by planned enrollment, is the only one that started in 2025, is one of 4 in phase 2/3, and was the 23rd registered.
313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.
Browse Keratoconus studies →5 of the 23 studies testing riboflavin in Keratoconus are open now, in 1 country. Recruiting first, the newest first:
Cornea and Laser Eye Institute · Sites in United States
Ages 18+ · Healthy volunteers
Cornea and Laser Eye Institute · Sites in United States
Ages 12+ · Healthy volunteers
Cornea and Laser Eye Institute · Sites in United States
Ages 12+ · Healthy volunteers
Kent Wellish MD
Ages 12+
By country, each count listing its studies:
Riboflavin: first FDA approval 1953 (M.V.I.-12 ADULT). What it is approved for, and how studies give it, is on its page →
Of the 37 Keratoconus studies recruiting now, 21 (57%) set no upper age limit and 11 (30%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.
This study: 10 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 16 · Phase 4 1
First in 2008; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 500 is above the median of 40 across 205 interventional studies indexed under Keratoconus.
Median enrollment 170 across the 23 interventional studies. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
Price Vision Group is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Price Vision Group has 3 studies filed under Keratoconus — fewer than ten, so there is no comparison to draw.
1 of the studies testing riboflavin in Keratoconus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04731727Kent Wellish MDTreating Corneal Thinning Conditions With CCL Vario Riboflavin (CXL) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing riboflavin in Keratoconus, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized study compares 2 variations of corneal crosslinking for treatment of keratoconus or corneal ectasia.
Subjects diagnosed with keratoconus or corneal ectasia are randomized to one of two corneal crosslinking light durations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with 0.1% riboflavin eye drops and pulsed 18 milliwatt/cm2 ultraviolet A light for 10 minutes
Combination Product: Riboflavin 0.1% ophthalmic solution and pulsed light
Treatment with 0.1% riboflavin eye drops non-pulsed 9 milliwatt/cm2 ultraviolet A light for 10 minutes
Combination Product: Riboflavin 0.1% ophthalmic solution and non-pulsed light
Drug page: Riboflavin
Use of riboflavin 0.1% eye drops and pulsed 18 milliwatt/cm2 ultraviolet A light for 10 minutes
Drug page: Riboflavin
Use of riboflavin 0.1% eye drops and non-pulsed 9 milliwatt/cm2 ultraviolet A light for 10 minutes
Change in maximum keratometry
assessed with corneal tomography
Time frame: 6 months
change in corrected distance visual acuity
assessed with Snellen chart
Time frame: 6 months
change in uncorrected distance visual acuity
assessed with Snellen chart
Time frame: 6 months
Plan to share: No — IPD may be shared upon individual request to the study contact
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Dec 2030, 62 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Riboflavin
Price Vision Group